What happened in this episode?
Andrew Huberman interviews Dr Chris Thompson, a Harvard Medical School professor and chief of interventional gastroenterology at Massachusetts General Hospital, on gut physiology, obesity and emerging metabolic treatments. Thompson outlines how the oesophagus, stomach, small bowel and colon contribute not only to digestion but to hormone signalling, including ghrelin, CCK, GIP, GLP-1 and peptide YY. He argues that fibre and fermented foods support the microbiome’s production of short-chain fatty acids such as butyrate, which he links to gut barrier function and satiety pathways.
The conversation turns to obesity medicines, with Thompson discussing GLP-1 drugs’ benefits and limitations, including nausea, muscle loss and what he describes as high discontinuation rates. He describes an off-label patient practice of “micro dosing” by decanting pen injectors into sterile vials, and warns that cycling on and off GLP-1s could worsen body composition if lean mass is not preserved.
Thompson also advocates earlier metabolic risk detection—citing fasting insulin as an early warning signal and noting tools such as CGMs, DEXA and measures of visceral and ectopic fat. He describes procedural innovations, from endoscopic suturing approaches informed by gastric bypass physiology to duodenal ablation intended to ‘reset’ diseased tissue and improve HbA1c. Looking ahead, he highlights AI-assisted endoscopy, robotics, and a pancreas-targeted GLP-1 gene therapy programme he says has entered clinical trials in the Netherlands.
